Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2019-12-02

Clinical Trial Update: Gallium-68 PSMA-11 PET in Patients With Biochemical Recurrence [Phase 2, Phase 3]

View source ↗

Summary

Clinical trial update on Gallium-68 PSMA-11 PET imaging in patients with biochemical recurrence of prostate cancer (Phase 2/Phase 3).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Gallium-68 PSMA-11 (Gallium-68 labeled PSMA-11)

Snippet

Sponsor: University of California, San Francisco | Conditions: Prostate Cancer | Phase 2, Phase 3 | Status: COMPLETED | Results posted: 2019-12-02